Nunzia Pharmaceutical Company
NUNZ
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 559.13% | 204.55% | 119,919.87% | 323,568.46% | 392.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 559.13% | 204.55% | 119,919.87% | 323,568.46% | 392.86% |
| Operating Income | -559.13% | -204.55% | -119,919.87% | -323,568.46% | -392.86% |
| Income Before Tax | -585.22% | -204.55% | -119,919.87% | 22.77% | -392.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -585.22% | -204.55% | -119,919.87% | 22.77% | -392.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -585.22% | -204.55% | -119,919.87% | 22.77% | -392.86% |
| EBIT | -559.13% | -204.55% | -119,919.87% | -323,568.46% | -392.86% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -400.00% | -- | -43,000.00% | 36.87% | -- |
| Normalized Basic EPS | -200.00% | -- | -- | 36.86% | -- |
| EPS Diluted | -400.00% | -- | -43,000.00% | 36.87% | -- |
| Normalized Diluted EPS | -200.00% | -- | -- | 36.86% | -- |
| Average Basic Shares Outstanding | 48.39% | 50.16% | 52.42% | 22.33% | 2.79% |
| Average Diluted Shares Outstanding | 48.39% | 50.16% | 52.42% | 22.33% | 2.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |